EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment

Dita Hasni, Debie Anggraini, Mutiara Anissa, Lieka Nugrahi Jaslindo

Psychopharmacology Bulletin · 29.10.2026 · 56 (4) · 141-152

DOI: 10.64719/pb.21624 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 29.10.2026. Verfasst von Dita Hasni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hasni, Department of Pharmacotherapy, Faculty of Medicine, Universitas Baiturrahmah, Padang, West Sumatra, Indonesia. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with schizophrenia who receive antipsychotics carry an elevated risk of thromboembolic disease, but hemostatic and inflammatory markers vary widely between patients given the same drug. This pilot study described D-dimer, C-reactive protein (CRP), and the neutrophil-to-lymphocyte ratio (NLR) in such patients, described the distribution of CYP2D6 rs1065852 and HTR2A rs6313 genotypes, and explored whether the biomarkers differ by genotype.

Method

In an observational, cross-sectional analysis, the first 22 consecutive adults with schizophrenia treated for at least 4 weeks at a psychiatric hospital in Padang, Indonesia, were studied. D-dimer and CRP were measured by sandwich enzyme-linked immunosorbent assay and the two polymorphisms by Kompetitive Allele-Specific PCR. Continuous variables are reported as median (interquartile range); groups were compared with the Mann-Whitney U test and correlations assessed by Spearman rank correlation, two-sided, at an alpha of .05.

Results

Genotyping succeeded for all 22 samples. For rs1065852, 15 participants (68.2%) were AG and 7 (31.8%) GG, with no AA homozygotes; for rs6313, 10 (45.5%) were TT, 11 (50.0%) CT, and 1 (4.5%) CC. No participant reached the prespecified hypercoagulability threshold of 500 ng/mL (0 of 22; exact 95% CI, 0%–15.4%); median D-dimer was 64.0 ng/mL. Median CRP was 0.78 mg/L and median NLR 1.62. No biomarker differed by genotype or sex (all P ⩾ .09).

Conclusion

Hemostatic and inflammatory activity was low in this small clinically stable sample, and no genotype signal emerged. A genotype-based risk score is premature; a larger prospective study with a more sensitive D-dimer assay is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaAntipsychotic AgentsHumansFemaleMaleAdultCross-Sectional StudiesFibrin Fibrinogen Degradation ProductsC-Reactive ProteinBiomarkersMiddle AgedPilot ProjectsGenotypeCytochrome P-450 CYP2D6Polymorphism, GeneticNeutrophilsInflammationPolymorphism, Single NucleotideIndonesia

Stichwörter der Autor:innen

5-HT2AC-reactive proteinantipsychotic agentscytochrome P-450 CYP2D6genotypereceptorschizophreniaserotonin

Substanzen

Fibrin Fibrinogen Degradation ProductsC-Reactive ProteinAntipsychotic Agentsfibrin fragment DBiomarkersCytochrome P-450 CYP2D6

Autor:innen und Institutionen

  • Hasni, Department of Pharmacotherapy, Faculty of Medicine, Universitas Baiturrahmah, Padang, West Sumatra, Indonesia.
  • Anggraini, Department of Clinical Pathology, Faculty of Medicine, Universitas Baiturrahmah, Padang, West Sumatra, Indonesia.
  • Anissa, Department of Psychiatric, Faculty of Medicine, Universitas Baiturrahmah, Padang, West Sumatra, Indonesia.
  • Jaslindo, Department of Anatomy, Physiology, and Radiology, Faculty of Medicine, Universitas Baiturrahmah, Padang, West Sumatra, Indonesia.

Zitieren

APA

Hasni, D., Anggraini, D., Anissa, M., & Jaslindo, L. N. (2026). Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment. Psychopharmacology Bulletin, 56(4), 141-152. https://doi.org/10.64719/pb.21624

Vancouver

Hasni D, Anggraini D, Anissa M, Jaslindo LN. Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment. Psychopharmacology Bulletin. 2026;56(4):141-152. doi:10.64719/pb.21624

BibTeX
@article{Hasni2026,
  author = {Hasni, Dita and Anggraini, Debie and Anissa, Mutiara and Jaslindo, Lieka Nugrahi},
  title = {Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {141--152},
  doi = {10.64719/pb.21624}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche